| Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317) |
|---|
| 04/23/2003 | CN1411809A Usage and composition of pyridine onium derivative for curing application |
| 04/23/2003 | CN1411800A Cosmetic composition and method |
| 04/23/2003 | CN1106390C Tachykinin receptor antagonist substituted methyl keto-morpholine crystal form |
| 04/23/2003 | CN1106389C Efficient enantioselective addition reaction using organozinc reagent |
| 04/23/2003 | CN1106384C Indoline-2-one derivatives, its preparing method and its medicinal compositions |
| 04/23/2003 | CN1106383C Estrogenic agents |
| 04/23/2003 | CN1106379C 2-propyl valeramide and 2-propyl valeramide derivative and medical use as anticonvulsants |
| 04/23/2003 | CN1106195C Use of thazolinedione derivatives and related antihyperglycemic agents in treatment of disease states at risk for progressing to non-insulin-dependent diabetes mellitus |
| 04/22/2003 | US6552225 Such as n-(2,3-dichloro-4-(methylaminosulphonyl)phenyl)-3,3,3-trifluoro-2-hydroxy-2 -methylpropanamide; diabetes, obesity, lactic acidaemia |
| 04/22/2003 | US6552223 N-hydroxacylamino compounds, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2003 | US6552216 Molecular model for VLA-4 inhibitors |
| 04/22/2003 | US6552203 Optionally oxygenated hydrogenated thiophenes, thiopyrans and thiomorpholines containing hydroxyethylamine groups |
| 04/22/2003 | US6552200 Intermediates useful for the preparation of antihistaminic piperidine derivatives |
| 04/22/2003 | US6552188 Unsymmetrical cyclic diamine compound |
| 04/22/2003 | US6552168 Inhibition of apoptosis via attenuation of caspase activity should therefore be useful in the treatment of human diseases where inappropriate apoptosis is prominent or contributes to disease pathogenesis |
| 04/22/2003 | US6552088 Biphenyl derivatives |
| 04/22/2003 | US6552086 For therapy of psychiatric and neurological disorders |
| 04/22/2003 | US6552081 Methods for treating disorders in which docosahexaenoic acid (DHA) levels are affected |
| 04/22/2003 | US6552077 Kidney disorders |
| 04/22/2003 | US6552071 Methods for treating cell death diseases and inflammation |
| 04/22/2003 | US6552067 EP4 receptor selective agonists in the treatment of osteoporosis |
| 04/22/2003 | US6552062 For therapy of central nervous system disorders; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea, and obesity |
| 04/22/2003 | US6552058 Oxazolidinedione derivatives and their use |
| 04/22/2003 | US6552057 Serotonin 5-HT3 receptor partial activator |
| 04/22/2003 | US6552044 Indane or dihydroindole derivatives |
| 04/22/2003 | US6552030 Inhibit human factor Xa; treating thrombotic activity; 3-((3,5-difluoro-6-(3-(1-methylimidazolin-2-yl)phenoxy)-4-((2-(1,2 -dihydoxyethyl)-4-hydroxy-5-ethoxytetrahydrofuran-3-yl)oxy)-pyridin-2 -yl)oxy)4-hydroxybenzamidine |
| 04/22/2003 | US6552029 For therapy of rheumatoid arthritis, psoriasis, graft v. host disease, asthma, atopic dermatitis, allergic rhinitis, allergic conjunctivitis, complications following percutaneous transluminal coronary angioplasty, thrombosis |
| 04/22/2003 | US6552028 Inhibiting the binding of eotaxin to chemokine-3 (ccr-3) receptor; antiasthmatics |
| 04/22/2003 | US6552022 Atherosclerosis in a mammal, pancreatitis, non-insulin dependent diabetes mellitus, coronary heart disease in a lowering serum lipid levels |
| 04/22/2003 | US6552020 Compositions including antibiotics and methods for using same |
| 04/22/2003 | US6552019 Inhibitors of p38 |
| 04/22/2003 | US6552017 Substituted heterocycle fused gamma-carbolines |
| 04/22/2003 | US6552008 Administering effective amount of a selected azo-pyrazole derivative for therapy of thrombocytopenia |
| 04/22/2003 | US6552004 Delivery system for entrapping charged macromolecules and a method for preparing same |
| 04/22/2003 | US6551990 Methods of inhibiting ectopic calcification |
| 04/22/2003 | US6551989 Preventing airway mucus production by administration of EGF-R antagonists |
| 04/22/2003 | US6551822 NL4 tie ligand homologue |
| 04/22/2003 | US6551810 Polypeptide retains the ability to dephosphorylate an activated MAP-kinase |
| 04/22/2003 | US6551627 Medicinal herbal compounds for the prevention and treatment of diabetes |
| 04/22/2003 | US6551622 Storage-stable hydrophilic therapeutic agent is prepared by formulating therapeutic proteins with hydrophobically-derivatised carbohydrates; drug delivery |
| 04/22/2003 | US6551618 Compositions and methods for delivery of agents for neuronal regeneration and survival |
| 04/22/2003 | US6551612 Methods for modulating the axonal outgrowth of central nervous system neurons |
| 04/22/2003 | US6551596 Fractions of Chlorella extract containing polysaccharide having immunomodulating properties |
| 04/22/2003 | US6551359 Laccase, an oxidation color dye, and solvent selected from among certain polyols and their ethers; dyeing methods and kits |
| 04/22/2003 | CA2308780C Novel derivatives of 2,3-methanoamino acids, process for their preparation and pharmaceutical compositions containing them |
| 04/22/2003 | CA2292673C Pharmaceutical compositions containing eletriptan hemisulphate |
| 04/22/2003 | CA2287054C 1,3,8-triazaspiro¬4,5|decanone compounds as orl1-receptor agonists |
| 04/22/2003 | CA2281580C Quinoxalinediones |
| 04/22/2003 | CA2253869C Substituted oxobutyric acids as matrix metalloprotease inhibitors |
| 04/22/2003 | CA2239187C Inhibitors of farnesyl protein transferase |
| 04/22/2003 | CA2098295C G protein-coupled glutamate receptors |
| 04/17/2003 | WO2003031969A1 Novel method of assaying immune activity |
| 04/17/2003 | WO2003031939A2 Protein modification and maintenance molecules |
| 04/17/2003 | WO2003031628A1 Secretory polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same |
| 04/17/2003 | WO2003031627A1 Platelet-origin polypeptides having sphingosine kinase activity and sphingosine kinase genes encoding the same |
| 04/17/2003 | WO2003031615A1 Lysophosphatidic acid synthase inhibitor |
| 04/17/2003 | WO2003031614A1 Low molecular weight gtpase rhot |
| 04/17/2003 | WO2003031606A2 Crystal structure of an aurora kinase catalytic domain, and use thereof |
| 04/17/2003 | WO2003031602A1 The oncolytic microorganisms expressing hsp and uses thereof |
| 04/17/2003 | WO2003031477A1 Carbohydrate binding domain containing fusion proteins for delivery of therapeutic and other agents, and compositions containing them |
| 04/17/2003 | WO2003031473A1 Leukocyte inactivation module |
| 04/17/2003 | WO2003031464A2 Remodeling and glycoconjugation of peptides |
| 04/17/2003 | WO2003031462A2 Nogo receptor-mediated blockade of axonal growth |
| 04/17/2003 | WO2003031447A2 Pyrimidine derivatives |
| 04/17/2003 | WO2003031445A1 5-methoxy-8-aryl-[1,2,4] triazolo [1,5-a] pyridine derivatives as adenosine receptor antagonists |
| 04/17/2003 | WO2003031444A1 Polycyclic compounds having anti-tumor activity |
| 04/17/2003 | WO2003031442A1 Heterocyclic compounds, oxazole derivatives, process for preparation of the same and use thereof |
| 04/17/2003 | WO2003031440A1 3,4-di-substituted maleimide compounds as cxc-chemokine receptor antagonists |
| 04/17/2003 | WO2003031438A1 3-[4-(substituted heterocyclyl)-pyrrol-2-ylmethylidene]-2-indolinone derivatives as kinase inhibitors |
| 04/17/2003 | WO2003031436A1 Heterocyclic compounds for use in the treatment of disorders of the urinary tract |
| 04/17/2003 | WO2003031434A1 Compounds and methods |
| 04/17/2003 | WO2003031432A1 Substituted piperidines and their use for the treatment of diseases related to the histamine h3 receptor |
| 04/17/2003 | WO2003031418A1 3,4-dihydro-1h-naphthalene derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/17/2003 | WO2003031415A1 Mibefradil-based compounds as calcium channel blockers useful in the treatment of hypertension and angina |
| 04/17/2003 | WO2003031414A1 Novel heterocyclic compound and anti-inflammatory agent |
| 04/17/2003 | WO2003031413A1 Quinoline derivatives, synthesis method, and medicines containing said derivatives |
| 04/17/2003 | WO2003031412A1 Piperidine compounds as muscarinic antagonists |
| 04/17/2003 | WO2003031410A1 Ligands of melanocortin receptors and compositions and methods related thereto |
| 04/17/2003 | WO2003031409A1 1h-indole derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/17/2003 | WO2003031407A2 β-LACTAMYL VASOPRESSIN VlaANTAGONISTS |
| 04/17/2003 | WO2003031406A2 Kinase inhibitor scaffolds and methods for their preparation |
| 04/17/2003 | WO2003031405A2 Methods for the synthesis of substituted purines |
| 04/17/2003 | WO2003031404A2 Processes for the preparation of substituted isoxazoles and 2-isoxazolines |
| 04/17/2003 | WO2003031400A1 Low-calcemic oxime analogs of 1alpha, 25-dihydroxy vitamin d3 |
| 04/17/2003 | WO2003031398A1 4'-methanesulfonyl-biphenyl derivatives as a highly selective cyclooxygenase-2 inhibitor |
| 04/17/2003 | WO2003031397A1 Acylsulfonamides as inhibitors of steroid sulfatase |
| 04/17/2003 | WO2003030993A1 2-amino-6-(2,4,5-substituted-phenyl)-pyridines for use as nitric oxide synthase inhibitors |
| 04/17/2003 | WO2003030944A2 Inhibition of stat-1 |
| 04/17/2003 | WO2003030941A1 Controlled release drug delivery composition comprising polycationic polymer and negatively charged pharmacologically active compound |
| 04/17/2003 | WO2003030939A1 Therapies for treating respiratory diseases |
| 04/17/2003 | WO2003030935A2 Adjuvants for nucleic acid vaccines |
| 04/17/2003 | WO2003030925A1 Angiogenesis drugs |
| 04/17/2003 | WO2003030914A1 Utilization of phosphatidylserine in the treatment of attention deficit syndrome (adhs) |
| 04/17/2003 | WO2003030912A1 Prostaglandin analogs as chloride channel opener |
| 04/17/2003 | WO2003030910A1 Pharmaceutical composition for the treatment of disorders of non-human mammals |
| 04/17/2003 | WO2003030905A1 Dihydroorotate dehydrogenase inhibitor |
| 04/17/2003 | WO2003030904A1 8-amino-[1,2,4]triazolo[1,5-a]pyridine-6-carboxylic acid amide |
| 04/17/2003 | WO2003030902A1 Imidazole derivates as anti-inflammatory agents |
| 04/17/2003 | WO2003030901A1 Arylsulphonyl-substituted tetrahydro- and hexahydro-carbazoles as 5-ht-6 receptor ligands |
| 04/17/2003 | WO2003030900A1 Remedies for attention-deficient/hyperreactivity disorder |